SPOTLIGHT -
Houston—The CustomVue refractive treatment (VISX/AMO) for patients with mixed astigmatism demonstrated good results at 6 months, according to Douglas D. Koch, MD.
Teprotumumab: First FDA-approved treatment for TED
Podcast: Wet AMD and the treatment burden on patients
Prevent Blindness to mark ‘Prevent Blindness Day’ on June 1
Podcast: AI/MR in ophthalmology: The future is now
Preservative-free latanoprost vs BAK-preserved latanoprost
Optos unveils ultra-widefield color image modality, offering increased retinal visualization to ophthalmologists